Articoli correlati a The LDN Book, Volume Two: The Latest Research on How...

The LDN Book, Volume Two: The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More: 2 - Brossura

Elsegood, Linda

 
9781603589901: The LDN Book, Volume Two: The Latest Research on How Low Dose Naltrexone Could Revolutionize Treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and More: 2
Brossura
ISBN 10: 1603589902 ISBN 13: 9781603589901
Casa editrice: Chelsea Green, 2020

Sinossi

A comprehensive examination of Low Dose Naltrexone—a little-known drug with big potential

“[LDN] raises hopes of reversing memory loss in old age.”—the Guardian

A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.

LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments.

Expanding on the information presented in The LDN Book, Volume 1, which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue, Volume 2 highlights the latest clinical trials, case studies, and research with explanations from a dozen medical professionals on how they are using LDN to help patients suffering from:


  • Chronic pain
  • Parkinson’s disease
  • Dermatologic conditions
  • Traumatic brain injury
  • Lyme disease and more

The LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.

Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

Informazioni sull'autore

Linda Elsegood is the founder of the LDN Research Trust, which was set up in the UK as a Registered Charity in 2004, and is the editor of The LDN Book. Diagnosed with MS in August of 2000, she started LDN therapy in December of 2003, and now has a better quality of life and hope for the future. Through the Trust, she has connected thousands of patients, doctors, and pharmacists around the world with information, articles, and patient stories about LDN.

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

Editore
Chelsea Green
Data di pubblicazione
2020
Lingua
Inglese
ISBN 10 
1603589902
ISBN 13 
9781603589901
Rilegatura
Copertina flessibile
Numero edizione
1
Numero di pagine
288
Contatto del produttore
non disponibile
Persona responsabile
GPSR Kontakt
gpsr@libri.de

Europaallee 1
Bad Hersfeld
36244
Germania